Form 8-K - Current report:
SEC Accession No. 0001628280-25-032959
Filing Date
2025-06-25
Accepted
2025-06-25 08:22:25
Documents
15
Period of Report
2025-06-25
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K ovid-20250625.htm   iXBRL 8-K 31469
2 EX-99.1 ovidexhibit2025-06x25.htm EX-99.1 12938
6 ovid-therapeutics_logo750sa.jpg GRAPHIC 23227
7 picture1a.jpg GRAPHIC 8150
  Complete submission text file 0001628280-25-032959.txt   209575

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20250625.xsd EX-101.SCH 1779
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20250625_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20250625_pre.xml EX-101.PRE 13044
18 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20250625_htm.xml XML 2720
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 251071096
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)